 | |
| Clinical data | |
|---|---|
| Trade names | Filspari |
| AHFS/Drugs.com | Micromedex Detailed Consumer Information |
| License data |
|
| Routes of administration |
By mouth |
| ATC code |
|
| Legal status | |
| Legal status |
|
| Identifiers | |
| KEGG | |
Sparsentan, sold under the brand name Filspari, is a medication used for the treatment of primary immunoglobulin A nephropathy. Sparsentan is an endothelin and angiotensin II receptor antagonist.
It was approved for medical use in the United States in February 2023.
Medical uses
Sparsentan is indicated to reduce proteinuria in people with primary immunoglobulin A nephropathy.
Society and culture
Legal status
Sparsentan is approved in the US under accelerated approval based on reduction of proteinuria.
External links
- Clinical trial number NCT03762850 for "A Study of the Effect and Safety of Sparsentan in the Treatment of Patients With IgA Nephropathy (PROTECT)" at ClinicalTrials.gov